QUESTION:
Use current research and clinical guidelines (published in the past 5 years) to discuss one (1) evidenced based treatment option for Type 2 Diabetes.
INSTRUCTIONS:
*Please use Australian clinical guidelines for this condition. APA 7th reference list and in text referencing. 350 words.*
Expert Solution Preview
Introduction:
Type 2 Diabetes is a growing epidemic, and its prevalence is increasing worldwide. It is a chronic condition characterized by high blood sugar levels resulting from the body’s resistance to insulin or insufficient insulin production. Patients with Type 2 Diabetes have an increased risk of developing cardiovascular diseases, kidney failure, and blindness. Therefore, the treatment of Type 2 Diabetes is an essential aspect of managing the disease and reducing the associated complications.
Treatment Options for Type 2 Diabetes:
The Australian Diabetes Society (ADS) and the National Heart Foundation of Australia (NHFA) have jointly developed clinical guidelines for the management of Type 2 Diabetes. According to the guidelines, the treatment of Type 2 Diabetes should be individualized, with the primary goal of achieving and maintaining optimal glycemic control while minimizing the risk of hypoglycemia, hypoglycemia unawareness, and other complications.
One evidenced-based treatment option for Type 2 Diabetes is the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, which are a class of antidiabetic drugs that work by inhibiting SGLT2, the protein responsible for reabsorbing glucose in the kidneys. This action mechanism promotes the excretion of glucose through the urine, resulting in a reduction of blood glucose levels.
Recent clinical trials have demonstrated the safety and efficacy of SGLT2 inhibitors in improving glycemic control and reducing the risk of cardiovascular events in patients with Type 2 Diabetes. For instance, the CREDENCE trial, a randomized controlled trial, showed that canagliflozin, an SGLT2 inhibitor, significantly reduced the risk of renal events and cardiovascular death in patients with Type 2 Diabetes and chronic kidney disease.
Furthermore, SGLT2 inhibitors have shown additional benefits in terms of weight loss, blood pressure reduction, and low rates of hypoglycemia compared to other antidiabetic medications such as sulfonylureas and insulin.
In conclusion, SGLT2 inhibitors have proven efficacy and safety in the management of Type 2 Diabetes. The use of these drugs, in combination with lifestyle modifications, regular monitoring of blood glucose levels, and other evidence-based treatments, can help patients achieve optimal glycemic control and reduce the risk of complications associated with Type 2 Diabetes.